NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company focused on antiviral drug development, announced that its Phase II clinical trial of NV-387 Oral Gummies for the treatment of Bundibugyo ebolavirus and other Ebola viruses is expected to commence soon in the Democratic Republic of Congo (DRC). The company has received regulatory approval from the local agency ACOREP to initiate the trial and has appointed Professor Patrick Katoto as principal investigator. Preparatory activities, including staff training, are underway, and the NV-387 drug product is already available in the DRC. First patient dosing is anticipated within a few weeks, barring outbreak-related impediments.
NV-387 is an orally administered broad-spectrum antiviral designed to mimic host-side features that viruses require for infection. The company believes that oral delivery could offer significant advantages in resource-limited outbreak settings compared to treatments requiring intravenous infusions, which are often logistically challenging in such environments. This is particularly relevant in the DRC, where Ebola outbreaks have historically occurred in remote areas with limited healthcare infrastructure.
Om Sai Clinical Research Private Limited is serving as the contract research organization (CRO) for this Phase II trial, as well as for the company’s planned Phase II trial of NV-387 Oral Gummies for the treatment of Mpox in the DRC. The selection of a CRO with experience in the region underscores the company’s commitment to conducting rigorous clinical trials in the affected areas.
The initiation of this trial represents a critical step in the development of NV-387, which is also being investigated for other viral infections, including RSV, COVID-19, influenza, and Mpox. The drug candidate is based on the company’s nanoviricide technology, which utilizes specially designed nanomaterials to target and neutralize viruses. NanoViricides holds a worldwide exclusive license to this technology for several viruses, including Ebola/Marburg viruses.
The potential impact of an effective oral antiviral for Ebola cannot be overstated. Current treatments for Ebola, such as monoclonal antibodies, require intravenous administration and cold chain storage, which are often unavailable in outbreak zones. An oral formulation could be distributed more easily and administered by community health workers, potentially improving patient outcomes and helping to contain outbreaks more effectively.
However, the path to regulatory approval is lengthy and uncertain. As with all drug development, there is no guarantee that NV-387 will demonstrate sufficient efficacy and safety in clinical trials. The company acknowledges these risks, noting that the typical drug development process is extremely lengthy and requires substantial capital. Nevertheless, the initiation of this Phase II trial marks a significant milestone for NanoViricides and for the global effort to combat Ebola.
The trial in the DRC is part of a broader strategy by NanoViricides to address neglected tropical diseases that pose significant public health threats. By advancing NV-387 through clinical trials, the company aims to provide a new tool in the fight against Ebola and other viral outbreaks, potentially saving lives and reducing the burden on healthcare systems in affected regions.
For more information, visit the full press release at https://ibn.fm/uWVTo.
